Navigation Links
Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
Date:3/27/2008

Bethesda, MD, March 27, 2008 The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.

This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The sweat test is the traditional diagnostic test for CF.

These early results are an extraordinary endorsement of our hypothesisthat small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis, said Robert J. Beall, Ph.D., president and CEO of the Foundation. The emerging data for VX-770 represents the most exciting results weve seen from a Phase 2 trial and increase our confidence that were on the right track.

The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technologyknown as high throughput screeningto find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the two organizations have closely collaborated to advance VX-770 and a second CF compound, known as VX-809, through research and into development.

At a time
'/>"/>

Contact: Laurie Fink
lfink@cff.org
301-841-2602
Cystic Fibrosis Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Cystic Fibrosis foundation lays out new treatment guidelines
6. Experts Release New Cystic Fibrosis Guidelines
7. Lung Transplants May Not Help Most Cystic Fibrosis Children
8. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
9. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
10. Montana Passes Newborn Screening Law for Cystic Fibrosis
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 As kinship ... for children who cannot live with their parents, emphasis ... to continue to enhance services and supports for kinship ... America’s (CWLA) National Kinship Care Conference is being held ... knowledge of best practice, policy, program and service development ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... July 1 AlphaMed Press, co-publisher of the journal ... stem cells and regenerative medicine, has promoted Miodrag Stojkovic ... is Deputy Director of the Prince Felipe Research Centre ... Spain. He led the team that first announced derivation ...
... ... two winners of their 2009 North American Grant Program. Exiqon had recently announced ... non-profit institutions across North America, engaged in microRNA research. , ... (PRWEB) July 1, 2009 -- Exiqon A/S ...
... ... the past 30 years, The Free Choice Foundation is a newly established grassroots organization ... with regards to healthcare. , ... Tokyo, Japan (PRWEB) July 1, 2009 -- Based on the spirit of ...
... Also recommends dosing limits for OTC products that contain ... liver damage. , TUESDAY, June 30 (HealthDay News) ... combine acetaminophen with an opiate narcotic, should be banned, ... like Tylenol or Excedrin, should be lowered, a U.S. ...
... Disease , , WASHINGTON, June 30 Today Lung ... Cancer illustrating again the devastating toll caused by lung cancer. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) ... analyzes the most recent available data from the National Institutes of ...
... Andrew Ordon, co-host of the syndicated talk show The ... a non-invasive skin contouring procedure, at his state-of-the-art surgical facilities ... is the perfect option for someone who wants to look ... explains Ordon. "There is little to no downtime with this ...
Cached Medicine News:Health News:STEM CELLS Promotes Miodrag Stojkovic to Editor 2Health News:Exiqon Announces 2009 North American Grant Award Winners 2Health News:Exiqon Announces 2009 North American Grant Award Winners 3Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 2Health News:FDA Panel Urges Ban on Vicodin, Percocet 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 4Health News:Lung Cancer Alliance Releases Updated 2009 Facts About Lung Cancer 2
(Date:9/17/2014)... TAMPA, Fla. , Sept. 17, 2014   ... announced today that Business Insurance magazine has ... Insurance" distinction for the third year in a row. ... joint effort of Business Insurance  and the Best ... evaluation, is open to all publicly or privately-held insurance ...
(Date:9/17/2014)... ANGELES and LEIPZIG, Germany ... today announced that it has entered into an ... the development of antibody-based imaging agents to image ... "Our collaboration with Novotectid expands ImaginAb,s capability to precisely ... immune-oncology and autoimmune disease areas. The ability to ...
(Date:9/17/2014)... PALO ALTO, Calif. , Sept. 17, 2014 /PRNewswire/ ... of the Company,s Phase 2 clinical program of NP001 ... Lou Gehrig,s disease) are being highlighted today ... of the ALS Research Group , being held in ... According to a  post hoc  analysis, administration of a ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Reportlinker.com announces that a new market research report ... Drug Delivery in Central Nervous System Diseases - ... The delivery of drugs ... in the treatment of neurological disorders. Drugs may ...
... Robbins & Myers, Inc. (NYSE: ... its Romaco businesses to a group of funds led ... investment firm.  Total consideration was approximately euro 65 million ... and euro 4 million of assumed liabilities and is ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Medicine Products: